Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results

Anavex Life Sciences to Participate at the BTIG Biotechnology Conference 2022

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022

Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022